Sign in

    Brandon Frith

    Research Analyst at Wolfe Research, LLC

    Brandon Frith is an Equity Research Associate at Wolfe Research, LLC, specializing in providing in-depth analysis for institutional clients across targeted market sectors. He began his career after graduating in 2024 with a finance degree from Loyola Marymount University and joined Wolfe Research directly out of college. While performance metrics and specific company coverage are not yet publicly reported due to his recent entry into the industry, his academic and early professional background indicate foundational expertise in financial research and valuation. Frith is expected to pursue professional securities licenses such as the FINRA Series 7 and 63 as part of his role at Wolfe Research.

    Brandon Frith's questions to Intellia Therapeutics (NTLA) leadership

    Brandon Frith's questions to Intellia Therapeutics (NTLA) leadership • Q2 2025

    Question

    On behalf of Andy Chen at Wolfe Research, Brandon Frith asked what specific data Intellia aims to generate with the expanded MAGNITUDE study to be compelling to payers and physicians.

    Answer

    EVP & CMO David Lebwohl explained that as tafamidis becomes the standard of care, it is critical to demonstrate a statistically significant and clinically meaningful benefit on top of it. CEO John Leonard added that the goal is to generate "absolutely unambiguous" data across the entire treatment spectrum—monotherapy, combination therapy, and standard of care—to clearly differentiate the product in the market.

    Ask Fintool Equity Research AI